Galmed Pharmaceuticals Lt... (GLMD)
NASDAQ: GLMD
· Real-Time Price · USD
1.43
-0.05 (-3.38%)
At close: Aug 15, 2025, 3:59 PM
1.47
3.14%
After-hours: Aug 15, 2025, 07:58 PM EDT
Galmed Pharmaceuticals Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | 9K | 15K | 32K | 41K | 40K | 43K | 26K | 17K | 18K | 19K | 30K | 40K | 42K | 32K | 21K | 11K |
Gross Profit | -74K | -83K | -89K | -106K | -41K | -40K | -43K | -26K | -17K | -18K | -19K | -30K | -40K | -42K | -32K | -21K | -11K |
Operating Income | -6.06M | -6.2M | -6.79M | -6.24M | -6.89M | -7.49M | -7.79M | -11.7M | -13.56M | -17.65M | -22.65M | -25.12M | -29.8M | -32.84M | -35.73M | -35.48M | -32.88M |
Interest Income | 103K | 229K | 364K | 364K | 539K | 585K | 450.75K | 480.75K | 202.75K | 30.75K | 218K | 319K | 335K | 562K | 374K | 928K | 1.2M |
Pretax Income | -7.35M | -7.52M | -6.32M | -5.88M | -6.36M | -6.91M | -7.54M | -11.41M | -13.55M | -17.87M | -22.68M | -25.04M | -29.7M | -32.47M | -35.29M | -34.48M | -31.61M |
Net Income | -7.35M | -7.52M | -6.32M | -5.88M | -6.36M | -6.74M | -7.55M | -11.46M | -13.6M | -18.13M | -22.76M | -25.09M | -29.76M | -32.47M | -35.29M | -34.48M | -31.61M |
Selling & General & Admin | 3.16M | 3.29M | 3.74M | 3.38M | 3.75M | 3.92M | 3.96M | 4.19M | 4.28M | 4.66M | 4.81M | 4.98M | 5.21M | 5.66M | 5.75M | 5.5M | 4.97M |
Research & Development | 2.98M | 2.98M | 3.03M | 2.85M | 3.12M | 3.57M | 3.83M | 7.51M | 9.28M | 12.99M | 17.88M | 20.18M | 24.64M | 27.22M | 29.98M | 29.98M | 27.91M |
Other Expenses | n/a | n/a | n/a | 556K | 556K | 556K | 556K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 6.14M | 6.27M | 6.77M | 6.23M | 6.88M | 7.49M | 7.79M | 11.7M | 13.56M | 17.65M | 22.69M | 25.16M | 29.84M | 32.88M | 35.73M | 35.48M | 32.88M |
Interest Expense | n/a | n/a | n/a | 5K | 5K | 5K | 195K | 220K | 224K | 275K | 128K | 98K | 94K | 43K | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | -9K | -15K | -15K | -15K | -6K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 6.14M | 6.28M | 6.79M | 6.24M | 6.89M | 7.49M | 7.79M | 11.7M | 13.56M | 17.65M | 22.69M | 25.16M | 29.84M | 32.88M | 35.73M | 35.48M | 32.88M |
Income Tax Expense | n/a | n/a | -37.81K | -37.81K | -37.81K | -209.81K | 18K | 48K | 44K | 267K | 37K | 7K | 11K | -40K | n/a | n/a | n/a |
Shares Outstanding (Basic) | 1.78M | 1.61M | 69.13K | 524.56K | 5.46M | 5.05M | 6.25M | 1.68M | 1.68M | 1.68M | 1.68M | 1.67M | 1.67M | 1.67M | 1.67M | 1.67M | 1.56M |
Shares Outstanding (Diluted) | 1.78M | 1.61M | 69.13K | 524.56K | 5.46M | 5.05M | 6.25M | 1.68M | 1.68M | 1.68M | 1.68M | 1.67M | 1.67M | 1.67M | 1.67M | 1.67M | 1.56M |
EPS (Basic) | -76.86 | -76.47 | -30.45 | -3 | -1.82 | -2.58 | -3.86 | -6.82 | -8.1 | -10.81 | -13.59 | -15 | -17.79 | -19.8 | -22.49 | -22.75 | -21.65 |
EPS (Diluted) | -76.86 | -76.47 | -30.45 | -3 | -1.82 | -2.58 | -3.86 | -6.82 | -8.1 | -10.81 | -13.58 | -14.99 | -17.78 | -19.79 | -22.49 | -22.75 | -21.65 |
EBITDA | -6.07M | -6.2M | -6.7M | -6.14M | -6.86M | -7.46M | -7.76M | -11.67M | -13.53M | -17.62M | -22.66M | -25.12M | -29.8M | -32.84M | -35.69M | -35.44M | -32.84M |
EBIT | -7.71M | -7.84M | -6.79M | -6.24M | -6.89M | -7.49M | -7.79M | -11.7M | -13.56M | -17.65M | -22.69M | -25.16M | -29.84M | -32.88M | -35.73M | -35.48M | -32.88M |
Depreciation & Amortization | 1.64M | 1.65M | 89K | 106K | 41K | 40K | 43K | 34K | 34K | 35K | 36K | 39K | 40K | 42K | 43K | 41K | 40K |